Spine BioPharma’s Phase III MODEL trial of its drug **SB-01** for chronic low back pain (CLBP) linked to degenerative disc disease (DDD) does not meet its primary endpoint. The trial evaluates SB-01’s efficacy in treating this condition, though results indicate the drug did not achieve the intended outcome.
Spine BioPharma’s phase 3 trial for its chronic low back pain treatment fails to meet the primary efficacy endpoint. The company attributes the result to an unexpectedly high sham response rate in the study. Researchers compare the drug’s performance against a placebo group to assess effectiveness.
Spine BioPharma finishes enrolling patients in its Phase 3 **MODEL trial**, testing **SB-01** as a treatment for chronic low back pain (CLBP). The trial assesses the drug’s safety and efficacy in addressing a condition affecting millions. SB-01 targets degenerative disc disease, a leading cause of persistent back pain. Enrollment completion marks a key milestone ahead of potential regulatory submissions.
Spine BioPharma begins Phase III trials for its SB-01 intradiscal pharmacologic treatment targeting pain-related disability from degenerative disc disease. The study marks the first patient enrollment in this pivotal phase. SB-01 aims to address a condition affecting millions with chronic spinal pain.
